

# National Toxicology Program Center for Phototoxicology (NCP)



Located at the
U.S. Food & Drug Administration's
National Center for Toxicological Research,
Jefferson Laboratories,
Jefferson, Arkansas





### **OUTLINE**

Stimulus for NCP

Challenge, Purpose, Product

**Oversight** 

**Facilities and Operation** 

Support

Studies in NCP

**Future Directions** 



"... to conduct mechanistic-based toxicity and carcinogenicity studies on FDA high priority chemicals nominated to the National Toxicology Program (NTP)..."



#### STIMULUS FOR NCP

Nomination of alpha hydroxy acids (~1998) to the NTP by FDA exposed deficiency regarding conduct of toxicology studies in presence of light.

Since humans are exposed simultaneously to terrestrial sunlight and chemicals (*e.g.* natural and anthropomorphic environmental chemicals, cosmetics, drugs) this deficiency needed to be addressed.



#### **DEFINITIONS**

## Phototoxicity -

toxicity of a chemical when irradiated with electromagnetic radiation.

## Photocarcinogenicity -

carcinogenicity of a chemical when irradiated with non-carcinogenic doses of electromagnetic radiation.

## Photococarcinogenicity -

the effect of a chemical on carcinogenic doses of electromagnetic radiation.



## Challenge -

develop a multi-study, multi-user facility for testing the phototoxicity, photocarcinogenesis, and photococarcinogenesis of chemicals.

#### Purpose -

conduct toxicology studies on the interaction of light with chemicals.

#### Product -

(1) toxicological data for public health decisions, chemicals <u>+</u> light; (2) NTP Technical Reports; (3) peer-reviewed scientific publications.



#### **OVERSIGHT**

NTP/FDA Toxicology Study Selection and Review Committee (TSSRC):

Biannual review of all NTP/FDA IAG studies, including NCP operation.

Peer-Review Working Group:

Photobiology and photophysics peer-review, regarding operation and direction of NCP (Aug. 2000; Sept. 2005)



#### **FACILITIES AND OPERATION**

Located at NCTR; Occupies ~5000 ft<sup>2</sup>

6 animal rooms, each max. of ~1000 mice,

1 multi-study exposure room,

1 control room

Paul C. Howard, PhD, Director Mary D. Boudreau, PhD, Manager Frederick A. Beland, PhD, Division Director



## LIGHT PRODUCING DEVICES FOR IRRADIATION OF ANIMALS

## **Sunlight simulation:**

6,500 Watt xenon arc solar simulators (2 horizontal, 1 vertical)

## **Ultraviolet B light:**

UVB fluorescent lamp exposure units (1 horizontal, 1 vertical, 2 benchtop)

## **Ultraviolet A light:**

UVA fluorescent lamp exposure (1 horizontal, 1 vertical, 2 benchtop)


Nd:YAG laser (1064, <u>532</u>, 355, 266 nm)






## 6.5 kW XENON ARC SOLAR LIGHT SIMULATOR - HORIZONTAL








## **EXPOSURE OF MICE TO 6.5 kW LIGHT**







#### **SPECTRUM OF 6.5 kW XENON ARC LIGHT**





Spectrum of xenon arc light is more similar to sunlight than commonly used fluorescent sunlamps.





# 6.5 kW XENON ARC SOLAR LIGHT SIMULATOR - VERTICAL







## **UVB FLUORESCENT LAMP UNITS**





## **UVA FLUORESCENT LAMP UNITS**








#### **DOSIMETRY**

Erythema Action
Spectrum (red line)
represents the
relationship of erythema
to the wavelength of light.

Multiplication of the 6.5 kW light spectrum (blue line) and EAS generates the weighted irradiance (magenta line).

 $3.095 \mu W-CIE/cm^2 \times 60$ sec = 186  $\mu J-CIE/cm^2/min$ 





#### **DOSIMETRY**


Typical photocarcinogenesis doses of simulated solar light are 0.3, 0.6, and 0.9 MED<sup>instrumental</sup>:

- 0.3 MED<sup>instrumental</sup>/day = 6.55 mJ-CIE/cm<sup>2</sup>/day
- 0.6 MED<sup>instrumental</sup>/day = 13.7 mJ-CIE/cm<sup>2</sup>/day
- 0.9 MED<sup>instrumental</sup>/day = 20.55 mJ-CIE/cm<sup>2</sup>/day



## **DOSIMETRY**

The Solar Light PMA 1101 dosimeter has approximately the same spectral response as skin to erythema




Erythema Action Spectrum --- SUV Detector





## **AVERAGE SPECTRUM OF LIGHT IN STUDY TR524**





## **AVERAGE DOSES OF LIGHT DELIVERED IN TR524**

	FEMALE	MALE
0.3 MED <sup>i</sup> /day 34.25 mJ-CIE/cm <sup>2</sup> /week	100.05%	100.26%
	100.24%	100.23%
<b>0.6 MED</b> <sup>i</sup> /day 68.5 mJ-CIE/cm <sup>2</sup> /week	100.06%	100.06%
	99.97%	100.13%
0.9 MED <sup>i</sup> /day 102.75 mJ-CIE/cm <sup>2</sup> /week	100.01%	100.06%



#### **ANIMAL HUSBANDRY**

```
Test animal
      SKH-1 (hr<sup>-</sup>/hr<sup>-</sup>); Tg.AC;
      TPras(+),p16/INK4a(+/-)
Stainless steel mouse housing/exposure racks
      90 units
Automatic watering system for racks
      6 rooms, 14 racks/room
Quarantine facility for receipt of off-site mice
NCTR breeding facility
      F344, B6C3F<sub>1</sub>, TP-ras(+),p16/INK4a(-/-)]
```





## SKH-1 (hr<sup>-</sup>/hr<sup>-</sup>) MOUSE





## **ANIMAL HOUSING/EXPOSURE**





#### MULTIGEN DATABASE FOR STUDY SUPPORT


Animal ID, location, test group
Operator ID and location
Animal treatment (e.g. cream, light)
Twice daily checked (am, pm)
Weekly animal weights and clinical observations recorded
Tumor size and location (weekly)
Animal disposition





#### **MEASUREMENT OF TUMOR SIZE**

<u>Past</u> – Caliper-based measurement, entry into animal database system.





#### **MEASUREMENT OF TUMOR SIZE**

#### Present -


- -digital image of animal;
- -downloaded into MultiGen database;
- -skin lesions measured using calibrated image analysis software.

#### Results in:

- -improved accuracy, and
- -ability for reexamination of tumor size (or aspect ratio, surface area, etc).




## **DIGITAL IMAGE SYSTEM**





## MEASUREMENT OF TUMORS: CALIBRATED SOFTWARE





#### STUDY SUPPORT

**Animal husbandry** 

Div. Veterinary Services, Animal Care Contractor, NCTR IACUC

MultiGen database

**Quality Assurance Unit** 

**Pathology** 

Necropsy, histopathology, tumor images, immunohistochemistry, TDMS

**Statistics** 

Div. Biometry and Risk Assessment, Statistics Contractor

Facilities, maintenance



#### STUDIES IN NCP

Alpha and beta hydroxy acids (*TR 524*)
Aloe vera (*PWG, fall 2006*)
Retinyl palmitate (*PWG, spring 2006*)
Furocoumarins (oxypeucedanin) (*completed*)
Nanoscale materials, dermal penetration/toxicity
(*in progress*)
Tattoo inks (*peer-review publications; in progress*)
Mouse melanoma model (*peer-review publications; completed*)



#### **FUTURE DIRECTIONS**

#### **Future studies**

Nanoscale material tumorigenicity in Tg.AC Permanent makeup ink/pigments Tattoo ink photocarcinogenicity

## Research and support

Biomarkers of skin cancer development, ACB-PCR *p53* mutations, gene expression (RNA, protein) Molecular pathology





## **NTP Center for Phototoxicology**



... meeting the electromagnetic radiation research and testing needs of the NTP and FDA.